Datapoint: Sanofi Inks Deal for Provention Bio
French drugmaker Sanofi on March 13 revealed it has entered a $2.9 billion deal to acquire Provention Bio. The transaction nets Sanofi Tzield, Provention’s immunotherapy that stalls the progression of type 1 diabetes in adult and some pediatric patients. “The acquisition is a strategic fit for Sanofi at the intersection of the company’s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet need, and its expertise in diabetes,” the company said in a press release. Tzield was first approved by the FDA in November 2021, and Evaluate Pharma projects the drug will see $149 million in global sales by the end of 2024, growing to $1 billion in 2028.